It posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion.
https://www.wsj.com/business/earnings/gsks-specialty-medicines-drive-solid-results-7b7cbfe3?mod=pls_whats_news_us_business_f